EpoBiomarkers Market, by Biomarker Type (Recombinant Human Erythropoietin,Erythropoietin Alfa, Erythropoietin Beta, Erythropoietin Zeta, ErythropoietinTheta, and Darbepoietin Alfa), by Application (End-stage Renal Disorder,Cancer, Rheumatoid Arthritis, AIDS, Myelodysplastic Syndrome, Neurology,Hematology, and Others), by End User (Diagnostic Centers, Hospitals, andAmbulatory Care and Surgical Centers), and by Region (North America, LatinAmerica, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook,and Opportunity Analysis, 2020 - 2027
Erythropoietin (Epo) is aglycoprotein hormone that consists 165 amino acids with four complexcarbohydrate chains attached to the peptide at four linkage sites. Epo adjustsred blood cell production to meet the tissue oxygen demand. Epo biomarkers areused for treating cancers and associated anemia, AIDS, and mostly in end-stagerenal disorders (ESRD). There are five different type of epo biomarkers.Commercially used epo for humans is known as recombinant human erythropoietin(rHuEPO).
Increasing research anddevelopment in epo biomarker technology and high prevalence of ESRD is expectedto boost growth of the global epo biomarker market. For instance, in 2015,Molecular Health — a cloud-based healthcare decision support technology thataids in evidence-based treatment decisions and improved outcomes — confirmedthe discovery that ephrin-type B receptor 4 (EPHB4) is an alternative eporeceptor.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/4057
Global Epo Biomarkers Market:Drivers
The epo biomarkers market isexpected to witness significant growth over the forecast period, owing toincreasing launch and adoption of erythropoietin alfa in cancer patients whoare suffering from anemia. For instance, in November 2018, Pfizer launched epoetinalfa biosimilar — Retacrit — at 33% discounted rate than the original drug inthe U.S. for treatment of anemia caused by chronic kidney disease andchemotherapy.
Furthermore, increasingprevalence of ESRD, which causes kidney failure and is often fatal is expectedto boost the market growth. According to the U.S. Renal Data System Annual DataReport of 2016, over 660,000 people in the U.S. were treated for kidney failureor ESRD. Out of these, 468,000 were dialysis patients and over 193,000 had a functioningkidney transplant.
Global Epo Biomarkers Market:Restraints
A major restraining factor forthe epo biomarkers market growth is the over-production of red blood cells dueto over-expression of epo biomarkers, which leads to absolute polycythemia andother conditions. Overproduction of epo may be an adaptive response associatedwith conditions that produce tissue hypoxia such as living at high altitude,chronic obstructive pulmonary disease, cyanotic heart disease, and sleep apnea.According to an article published in Biospace Journal in 2015, in the U.S.between 40% and 90% of cancer patients suffer from chemotherapy-induced anemia.Use of epo in cancer patients that suffer from chemotherapy-induced anemia wasrestricted by the Food and Drug Administration (FDA) due to increasing adverseevents including decreased survival and increased risk of tumor progression andrecurrence.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/epo-biomarkers-market-4057
Global Epo Biomarkers Market:Regional Analysis
North America is expected to holda dominant position in the epo biomarkers market over the forecast period,owing to robust healthcare infrastructure and increasing prevalence of cancerin the region. According to World Health Organization’s (WHO) 2018 report,around 609,640 deaths were recorded due to cancer and around 1.7 million newcases of cancer were diagnosed in 2018 in the U.S.
Asia Pacific is expected towitness significant growth in the epo biomarkers market, owing to presence ofmajor companies such as 3Sbio Group, Biocon Ltd., Genscript, IntasPharmaceuticals Ltd., Kyowa Hakko Kirin Co., Ltd., and Shandong KexingBioproducts Co. Ltd. Moreover, increasing prevalence of AIDS in India, China,Pakistan, and Bangladesh is also contributing to epo biomarker market growth.For instance, according to the UNAIDS Data 2018 for Asia Pacific region, inIndia 2.1 million people are living with HIV AIDS at the end of 2017.
Global Epo Biomarkers Market:Competitive Landscape
Key players operating in theglobal epo biomarkers market include, 3Sbio Group, Agilent Technologies, Inc., Amgen Inc., Bioagilytix Labs,Biocon Ltd., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., GalenicaAg, Genscript, Glaxosmithkline Plc., Intas Pharmaceuticals Ltd., Johnson &Johnson, Inc., Kyowa Hakko Kirin Co., Ltd., Teva Pharmaceutical IndustriesLtd., Merck Kgaa, Myriad Rbm, Novartis Ag, Pacific Biomarkers, Pfizer Inc.,Shandong Kexing Bioproducts Co. Ltd., Siemens Ag, and Thermo Fisher Scientific.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/4057
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
